9/14/2009

The FDA approved telavancin, a treatment for adults with skin infections caused by methicillin-resistant Staphylococcus aureus and other Gram-positive bacteria. Theravance and partner Astellas Pharma plan to launch the product as the brand Vibativ in the fourth quarter.

Related Summaries